chemicals
Commented by Fabian Lorenz on March 8th, 2023 | 16:22 CET
Nel share slumps, a 60% chance with Bayer, Almonty Industries and BASF
The Nel share was one of the big daily losers yesterday. As a result, the upward trend has finally been broken, and analysts' opinions differ widely. Berenberg sees the BASF share as a hold after the publication of the quarterly figures. The price target is EUR 55. The figures are in line with expectations. However, the end of share buybacks and concerns about future competitiveness weigh on the stock. By contrast, analysts see up to 60% upside potential for Bayer. Almonty Industries is benefiting from the boom in electromobility and also defense spending. As the leading tungsten producer outside China, analysts suspect it could soon come to a bidding war.
Read
Commented by Juliane Zielonka on March 3rd, 2023 | 10:00 CET
Rheinmetall, Defense Metals, BASF - Rearmament in the defense industry, restructuring in the chemical industry
A new chapter can begin for Ukraine's defense. Rheinmetall will supply the country with border surveillance technology. Analysts raise the share price target from EUR 240 to EUR 300. A solution to the conflict with Russia is not in sight, so demand for rare metals urgently needed in armaments is rising all the higher. This is where Defense Metals comes into play. The Canadian explorer has initial data from the crushing samples and can now better estimate the costs for the feasibility study. BASF is also concerned with costs. The Company put its red pen to work and cut 2/3 of its jobs, especially at a site in Germany. A planned agar project in the US has also been suspended until further notice.
Read
Commented by Juliane Zielonka on February 15th, 2023 | 12:01 CET
Altech Advanced Materials, Volkswagen, BASF - Innovative strength pushes growth
In the hunt for the precious raw materials needed for the energy transition, carmaker Volkswagen now has Canada on its radar. There, the Company wants to extract the lithium it so urgently needs for electric batteries. The Company would do well to reorganize its supply chains, and the EU is pushing for a CO2-friendly transformation of the automotive industry. The Company Altech Advanced Materials promises a higher performance of electric batteries. Its innovative technology allows electric batteries to perform better, which is ideal for the energy turnaround demanded by politicians. Chemical giant BASF is experiencing that politics cannot always be to the advantage of its own company. Once again, it is the EU that wants to ban a product...
Read
Commented by Fabian Lorenz on January 25th, 2023 | 13:54 CET
Bayer shares soon to reach triple digits? Barrick Gold and Desert Gold praised by analysts
Will Bayer be broken up, or will triple-digit share prices beckon? According to media reports, more and more investors are calling for the former. Most recently, Bluebell Capital Partners. According to the Bloomberg news agency, the British investor is calling on the DAX-listed Company to separate its Crop Science and Pharmaceuticals divisions. This could lead to a 70% increase in value for shareholders. Analysts also see considerable share price potential and believe that triple-digit prices are possible. Gold is also shining again. However, this has yet to be realized by exploration companies in particular. Experts see the chance of a revaluation at Desert Gold, for example - through takeover fantasy and drilling results. Besides B2Gold, Barrick Gold also comes into question as a buyer. The industry leader is also recommended as a buy, despite weakening Q4 results.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read
Commented by Armin Schulz on December 14th, 2022 | 11:54 CET
Nvidia, Meta Materials, BASF - High-tech stocks in focus
Interest rate hikes this year put pressure on the share price of many high-tech stocks. The NASDAQ has lost over 27% in the last year. It has hit second-tier stocks in particular, but big players such as Amazon, Facebook and Google have also lost ground. On December 13, the US inflation figures were lower than expected at 7.1%. Today, Wednesday, the next interest rate decision by the FED is due. Both news could lead the way for the coming weeks, as the NASDAQ has been bottoming out since October.
Read
Commented by Juliane Zielonka on December 8th, 2022 | 09:38 CET
BASF, Kleos Space, Amazon - With Big Data to share price success
For investors, the stock market remains a marketplace of innovations. But which company manages to expand its market power further? The ailing BASF Group relies on Big Data in the production processes of its subsidiary in the USA. A smart move, given the horrendous energy prices in Germany. Kleos Space is betting on space and, thanks to Elon Musk's SpaceX, is launching new satellites into space and, at the same time, cooperating with a data platform that was created around Airbus Defense. Amazon AWS is also betting on cooperation. The group is providing IT for cloud migration for a major US insurance company. Find out what exactly data predictions have to do with unscented body lotions here.
Read
Commented by André Will-Laudien on November 30th, 2022 | 11:58 CET
What to buy cheap? BYD and Uniper, BASF and Manuka Resources are on the rise
Even if BYD delivers close to 100,000 vehicles to Sixt in the next few years, this is not a guarantee for rising share prices. After all, major shareholder Warren Buffet is divesting his Chinese hobby horse. Does he know more? Is it a portfolio decision, or does he want to preemptively counter possible geopolitical surprises related to Taiwan? We do not know. The fact remains: Buffet has a lot of followers, and that is forcing the BYD price further and further down. Meanwhile, BASF reports good numbers and pushes further north with a seasonally firm DAX - who would have thought? We dive a little deeper.
Read
Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET
New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check
As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.
Read
Commented by Fabian Lorenz on October 12th, 2022 | 11:33 CEST
TUI share soon to be a penny stock? BASF, BioNTech, Cardiol Therapeutics - buy or sell?
Buy or sell? It is not only the BASF share that is currently the subject of clearly differing opinions. While the gas price brake plans on Monday caused euphoria among investors and correspondingly rising prices for the shares of the chemical company, analysts from Goldman Sachs and Morgan Stanley continue to express pessimism. Experts are similarly cautious about the prospects for TUI. UBS even sees the share of the tourism group on the way to becoming a penny stock. Analysts are more optimistic about BioNTech, but the share is not making any headway at the moment. In contrast, experts see massive upside potential in the biotech gem Cardiol Therapeutics. Cash is now equal to market capitalization, and drug development is making progress.
Read